Chapter

The role of biologicals in the treatment of lupus nephritis

Amara N. Ezeonyeji and David A. Isenberg

in Rheumatology and the Kidney

Second edition

Published on behalf of Oxford University Press

Published in print April 2012 | ISBN: 9780199579655
Published online February 2013 | e-ISBN: 9780191763472 | DOI: http://dx.doi.org/10.1093/med/9780199579655.003.0035

Series: Oxford Clinical Nephrology Series

The role of biologicals in the treatment of lupus nephritis

Show Summary Details

Preview

1. Over the last few years, treatment of SLE and LN has moved from serendipity to immunological sense focusing on biological agents that target the cells and molecules specifically involved in the critical pathways in SLE pathogenesis. 2. Biological agents offer the possibility of efficacious and safe treatment options for patients with refractory disease, reducing the burden of immunosuppressive drugs. 3. In spite of some recent disappointing results with biological, including abatacept and rituximab, a number of newer agents have shown encouraging benefits. 4. Belumimab and epratuzumab have both met their primary end-points in the BLISS-52, BLISS-76 and epratuzumab phase IIb trials, and rontalizumab and tociluzumab have shown promising results in phase I studies.

Chapter.  4734 words. 

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.